TFRC and Alzheimer disease: Clinical trials with TfR antibodies as BBB carriers have been initiated by Roche (to deliver Aβ-antibody for treatment of Alzheimer’s disease) and by JCR Pharma (to deliver iduronate-2-sulfatase enzyme for treatment of Mucopolysaccharidosis II) [42].